PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Videos|October 1, 2024
AAPS PharmSci 360 2024: Flex Manufacturing
Author(s)Susan Haigney
Pharmaceutical Technology sat down with Anna Jenks, director of Pharmaceutical Operations for Merck & Co., Inc. in Rahway, NJ, USA to talk about her prologue presentation for AAPS PharmSci 360 2024.
Advertisement
As a preview of what’s to come at this year’s AAPS PharmSci 360, being held Oct. 20–23, 2024 in Salt Lake City, UT, Pharmaceutical Technology® sat down with Anna Jenks, director of Pharmaceutical Operations for Merck & Co., Inc. (known as MSD outside of the United States and Canada) in Rahway, NJ, USA to talk about her
“Flexible manufacturing really relates to the industry and the needs of the industry,” says Jenks in the interview. “I think, from [a] historical facility standpoint, oftentimes we build fixed facilities that are harder to change. Flexible manufacturing looks at what we need now, but also is looking at what we need in the future, and even recognizing we don't know everything that we need, and we need to be able to change in the future when that need comes.”
At Merck & Co., Inc., Rahway, NJ, USA, Jenks states that they are focused on using flex manufacturing in clinical stage manufacturing but are looking to also apply it to commercial manufacturing.
“The clinical manufacturing has a short-term turnaround,” Jenks says. “Oftentimes, you see many short campaigns that are on days to weeks timeframe[s] and need fast switchover from one to the next, whereas the commercial manufacturing oftentimes has low, longer timeframes. So, you're looking, in a few years, [at] what kind of process train might be needed, and how are those retrofits going to occur. So the needs of flexible manufacturing might be slightly different, but the concepts definitely apply.”
Click the above video to watch the full interview.
Jenks’ prologue can be viewed on the
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
The IMA Pharmaceutical and MedTech divisions will be highlighting the TILE-X fill-finish line, a new VPHP BioIndicator, X-PEN autoinjector platform, and a range of machines from its IMA Active, IMA Life, IMA Safe, and IMA BFB divisions at the CPHI Milan event.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss navigating CMC requirements for new modalities and AI’s involvement in CMC.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.
The finalists for the 2026 CPHI Pharma Awards span 15 categories including API development, digital transformation, manufacturing, supply chain, sustainability, and leadership, with winners revealed October 6 at CPHI Milan.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Advertisement
Advertisement